key: cord-0682248-lcs9fqhq authors: Pinato, David J.; Scotti, Lorenza; Gennari, Alessandra; Colomba-Blameble, Emeline; Dolly, Saoirse; Loizidou, Angela; Chester, John; Mukherjee, Uma; Zambelli, Alberto; Aguilar-Company, Juan; Bower, Mark; Galazi, Myria; Salazar, Ramon; Bertuzzi, Alexia; Brunet, Joan; Mesia, Ricard; Sita-Lumsden, Ailsa; Colomba, Johann; Pommeret, Fanny; Seguí, Elia; Biello, Federica; Generali, Daniele; Grisanti, Salvatore; Rizzo, Gianpiero; Libertini, Michela; Moss, Charlotte; Evans, Joanne S.; Russell, Beth; Wuerstlein, Rachel; Vincenzi, Bruno; Bertulli, Rossella; Ottaviani, Diego; Liñan, Raquel; Marrari, Andrea; Carmona-García, M. Carmen; Sng, Christopher CT.; Tondini, Carlo; Mirallas, Oriol; Tovazzi, Valeria; Fotia, Vittoria; Cruz, Claudia Andrea; Saoudi-Gonzalez, Nadia; Felip, Eudald; Roqué Lloveras, Ariadna; Lee, Alvin J.X.; Newsom-Davis, Thomas; Sharkey, Rachel; Chung, Chris; García-Illescas, David; Reyes, Roxana; Sophia Wong, Yien Ning; Ferrante, Daniela; Marco-Hernández, Javier; Ruiz-Camps, Isabel; Gaidano, Gianluca; Patriarca, Andrea; Sureda, Anna; Martinez-Vila, Clara; Sanchez de Torre, Ana; Rimassa, Lorenza; Chiudinelli, Lorenzo; Franchi, Michela; Krengli, Marco; Santoro, Armando; Prat, Aleix; Tabernero, Josep; Van Hemelrijck, Mieke; Diamantis, Nikolaos; Cortellini, Alessio title: Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study date: 2021-04-06 journal: Eur J Cancer DOI: 10.1016/j.ejca.2021.03.035 sha: 970b21e7cc5ea567d4c656c628055e93fd7f8b47 doc_id: 682248 cord_uid: lcs9fqhq BACKGROUND: Despite high contagiousness and rapid spread, SARS-CoV-2 has led to heterogeneous outcomes across affected nations. Within Europe, the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100.000 as of January 2021. We aimed to compare the national impact of COVID-19 on the risk of death in UK cancer patients versus those in continental Europe (EU). METHODS: We performed a retrospective analysis of the OnCovid study database, a European registry of cancer patients consecutively diagnosed with COVID-19 in 27 centres from February 27 to September 10, 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline, including oncological and COVID-19 specific therapy across UK and EU cohorts and evaluated the association of these factors with the risk adverse outcome in multivariable Cox regression models. FINDINGS: Compared to EU (n=924), UK patients (n=468) were characterised by higher case fatality rates (40.38% versus 26.5%, p<0.0001), higher risk of death at 30 days (hazard ratio, HR 1.64 [95%CI 1.36-1.99]) and 6 months after COVID-19 diagnosis (47.64% versus 33.33%, p<0.0001, HR 1.59 [95%CI 1.33-1.88]). UK patients were more often males, of older age and more co-morbid than EU counterparts (p<0.01). Receipt of anticancer therapy was lower in UK versus EU patients (p<0.001). Despite equal proportions of complicated COVID-19, rates of intensive care admission and use of mechanical ventilation, UK cancer patients were less likely to receive anti-COVID-19 therapies including corticosteroids, anti-virals and interleukin-6 antagonists (p<0.0001). Multivariable analyses adjusted for imbalanced prognostic factors confirmed the UK cohort to be characterised by worse risk of death at 30 days and 6 months, independent of patient’s age, gender, tumour stage and status, number of co-morbidities, COVID-19 severity, receipt of anticancer and anti-COVID-19 therapy. Rates of permanent cessation of anticancer therapy post COVID-19 were similar in UK versus EU. INTERPRETATION: UK cancer patients have been more severely impacted by the unfolding of the COVID-19 pandemic despite societal risk mitigation factors and rapid deferral of anticancer therapy. The increased frailty of UK cancer patients highlights high-risk groups that should be prioritised for anti-SARS-CoV-2 vaccination. Continued evaluation of long-term outcomes is warranted. , Salvatore Grisanti 22 6 . Understanding whether there is regional variation in the natural course of COVID-19 is of utmost importance in the context of a still unresolved healthcare crisis. Such effort not only helps portraying the healthcare system response to COVID-19 but can also aid characterisation of geographical heterogeneity in the clinical characteristics underlying the vulnerability of cancer patients to SARS-CoV-2 infection. In addition to regional differences to case fatality rates from COVID-19, it is important to understand whether deferral and discontinuation of SACT recommended at the onset of the pandemic 14 might have impacted on the overall survival of patients with cancer in the UK, a population that is already characterised by poorer 5-year survival outcomes in a number of solid tumours 15 . In an attempt to prevent indiscriminate deferral of therapy, which is known to affect oncological outcomes in cancer [16] [17] [18] , in March 2020 the UK National Health Service identified 6 priority levels for SACT based on treatment intent and expected efficacy so that treatment can proceed for those where benefits clearly outweigh risks 19 . In this ad-hoc analysis of the OnCovid registry, we aimed to compare and contrast the risk of death following diagnosis of COVID-19 in cancer patients diagnosed in the UK versus those diagnosed in continental Europe. OnCovid (NCT04393974) is an active European registry study that has collected, since the beginning of the pandemic, consecutive patients fulfilling the following As primary endpoint of our study we elected the all-cause 30-days risk of death, a measure that mirrors endpoints utilized in clinical trials of COVID-19 therapeutics 21 . In view of the extended length of follow up of our cohort compared to earlier studies reporting case fatality rates censored at 14 days of observation [6] [7] [8] [9] 22, 23 , we reported, as additional study endpoint, all-cause risk of death at 6 months following COVID-19 diagnosis. The choice of this additional endpoint allowed us to preliminary investigate determinants of longer-term prognosis in COVID-19 survivors [24] [25] [26] . In comparing outcomes from UK and EU patients, we evaluated the distribution of baseline characteristics already known to be major determinants of mortality [6] [7] [8] 22, 23 . These included gender, age, number of co-morbidities, smoking history, tumour type (clustered as: breast, gastro-intestinal, gynecological/genito-urinary, hematological, thoracic, and others) [7] [8] [9] 27 , tumour stage (defined as advanced versus non-advanced J o u r n a l P r e -p r o o f according to disease-specific criteria), tumour status (presence of active versus nonmeasurable disease), receipt of anticancer or anti-COVID-19 therapy, and occurrence of complicated COVID-19 as described before 6 . The role of each determinant of mortality was explored across the two cohorts using univariable analysis. Accounting for their unbalanced distribution across cohorts, a fixed multivariable regression analysis model was adopted to verify their independent prognostic role. The differential distribution across UK and EU patients of other characteristics of interest including hospitalization and intensive care unit (ICU) admission rates, need for supplemental oxygen therapy and assisted ventilation, emergence of COVID-19 related complications and receipt of COVID-19-specific therapy were also reported as described previously 6, 23 . In addition, we reported rates of permanent discontinuation of anticancer therapy among those patients who were listed as receiving anticancer therapy at COVID-19 diagnosis, including only patients alive after 30 days since COVID-19 diagnosis. Authority ( OnCovid acknowledges infrastructural support from the Imperial College Biomedical Research Centre. The corresponding author had full access to all of the data and the final responsibility to submit for publication. At database lock, the registry included 1559 patients consecutively diagnosed with COVID-19. A total of 167 patients were excluded due to missing outcome data The high proportion of asymptomatic transmission has made SARS-CoV-2 a rapidly escalating global threat. However, mortality from COVID-19 is unevenly distributed across affected countries 28 Our ad hoc analysis of the OnCovid registry confirms that UK cancer patients were 1.5 times more likely to die from COVID-19 compared to patients enrolled from EU countries. In line with many other studies, our analysis confirms that exposure to anticancer therapy plays no role on the 30-days risk of death from COVID-19 6, 9, 23, 30 . Interestingly, UK patients were less likely to be receiving anticancer therapy at the moment of COVID-19 diagnosis. This is likely to reflect, at least in part, the rapid Interestingly, patients in the UK cohort were less likely to have received specific anti-COVID-19 therapy, a factor that emerged to be protective for 30-days and 6-months risk of death following adjustment for COVID-19 severity. When considering anti-COVID-19 therapies in detail (Supplementary Table 2 Another important aspect that should be considered in interpreting our results is hospital capacity, one of the determining factor for the overall COVID-19 mortality in UK during the first wave 28 . In our study, we report a higher hospitalization rate for UK therapies, infections diagnosed in the so-called "second wave" might be characterized by improved outcomes: a hypothesis that we aim to test when clinical data from our registry are fully mature. Similarly, whilst our study relies on significantly longer follow-up time compared to earlier reports, more mature survival data will allow us to provide further insight on the topic of long-term outcomes from COVID-19. Despite attempting to control for key clinicopathologic factors, our analyses might still be affected by unmeasured bias. For instance, we lack data on quantitative estimation of SARS-CoV-2 viral load, a parameter associated to disease severity and mortality from COVID-19 42 and that might have given us insight into severity of community exposure or underlying immune dysfunction in our study participants [43] [44] [45] . Notwithstanding the acknowledged limitations, this study provides a comprehensive, AC and DJP had full access to all data in the study and take responsibility for data integrity and analysis. and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; research funding from Roche and Novartis; and consulting/advisory role for NanoString Technologies JT reports personal financial interest in form of scientific consultancy role for Array Biopharma Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19 Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) UK Government Office of National Statistics. Number of Coronavirus (COVID-19) cases and risk in the UK Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal Progress in cancer survival, mortality, and incidence in seven high-income countries 2): a population-based study The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel) Real estimates of mortality following COVID-19 infection Defining causality in COVID-19 and neurological disorders A method for deciding which pre-existing condition mentioned on death certificates is the main pre-existing condition Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study Did hospital capacity affect mortality during the pandemic's first wave? Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study The prevalence and outcomes of frailty in older cancer patients: a systematic review Fair Allocation of Scarce Medical Resources in the Time of Covid-19 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial Remdesivir for the Treatment of Covid-19 -Preliminary Report Covid-19: New UK variant may be linked to increased death rate, early data indicate SARS-CoV-2 viral load is associated with increased disease severity and mortality Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19 and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; research funding from Roche and Novartis; and consulting/advisory role for NanoString Technologies Informed consent was waived by competent authorities due to anonymized nature of patient data and retrospective design of the study.